Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
publish chart | backtests Type: candle | line | advanced    Timeframe: intraday | daily | weekly | monthly  Settings
PRGO [NASD]
Perrigo Co.
Healthcare | Drug Related Products | USA
financial highlights | statements
IndexS&P 500 P/E26.08 EPS (ttm)4.56 Insider Own0.22% Shs Outstand94.04M Perf Week-0.47%
Market Cap11.18B Forward P/E17.99 EPS next Y6.61 Insider Trans-74.67% Shs Float92.24M Perf Month-0.08%
Income430.51M PEG2.07 EPS next Q1.57 Inst Own76.47% Short Float2.98% Perf Quarter3.85%
Sales3.40B P/S3.28 EPS this Y14.75% Inst Trans-1.63% Short Ratio5.40 Perf Half Y16.62%
Book/sh23.65 P/B5.03 EPS next Y17.62% ROA10.09% Target Price126.57 Perf Year17.61%
Cash/sh3.20 P/C37.17 EPS next 5Y12.60% ROE21.55% 52W Range98.71 - 121.33 Perf YTD14.40%
Dividend0.36 P/FCF24.75 EPS past 5Y41.51% ROI11.91% 52W High-1.99% Beta0.69
Dividend %0.30% Quick Ratio1.50 Sales past 5Y18.33% Gross Margin35.77% 52W Low20.47% ATR2.06
Employees8800 Current Ratio2.52 Sales Q/Q18.23% Oper. Margin19.39% RSI (14)51.06 Volatility1.80% 1.65%
OptionableYes Debt/Eq0.62 EPS Q/Q-3.69% Profit Margin12.65% Rel Volume0.79 Prev Close117.86
ShortableYes LT Debt/Eq0.60 EarningsMay 07 BMO Payout7.41% Avg Volume509.28K Price118.92
Recom2.20 SMA200.00% SMA500.29% SMA2006.06% Volume403,796 Change0.90%
25-Feb-13Upgrade UBS Neutral → Buy $115 → $130
12-Feb-13Reiterated Deutsche Bank Hold $110 → $115
04-Feb-13Upgrade Canaccord Genuity Hold → Buy $128
04-Feb-13Reiterated RBC Capital Mkts Sector Perform $109 → $111
28-Jan-13Initiated RBC Capital Mkts Sector Perform $109
08-Nov-12Downgrade Caris & Company Buy → Above Average $136 → $129
05-Nov-12Upgrade Barrington Research Mkt Perform → Outperform $142
14-Sep-12Upgrade Caris & Company Above Average → Buy $131 → $136
12-Jul-12Downgrade Canaccord Genuity Buy → Hold $125 → $125
15-May-12Initiated Stifel Nicolaus Buy $125
19-Apr-12Downgrade Caris & Company Buy → Above Average
17-Apr-12Initiated Auriga Buy $125
05-Mar-12Upgrade Canaccord Genuity Hold → Buy $125
05-Mar-12Reiterated UBS Buy $115 → $120
28-Oct-11Upgrade Caris & Company Above Average → Buy $120 → $125
03-Oct-11Initiated Deutsche Bank Hold $100
28-Sep-11Reiterated UBS Buy $100 → $115
28-Sep-11Reiterated Collins Stewart Buy $100 → $117
28-Sep-11Reiterated Caris & Company Above Average $106 → $120
22-Jul-11Reiterated Caris & Company Above Average $104 → $109
23-May-13 11:01AM  Perrigo to transfer stock to NYSE AP
08:15AM  Perrigo to transfer common listing to NYSE from Nasdaq theflyonthewall.com
08:15AM  InPlay: Perrigo to transfter common stock listing to NYSE from the NASDAQ Global Select Market Briefing.com
08:14AM  Perrigo To Transfer Common Stock Listing To NYSE PR Newswire
01:27AM  PERRIGO CO Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transf EDGAR Online
20-May-13 09:51AM  2 Healthcare Companies And 1 Consumer Goods Company With Recent Intensive Insider Selling at Seeking Alpha
18-May-13 08:00AM  The New Generic-Drug Battle Front at Motley Fool
17-May-13 11:50AM  Good News For Health Care Stocks Part 2 at Motley Fool
16-May-13 09:38AM  PERRIGO CO Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits EDGAR Online
15-May-13 03:50PM  Perrigo Stock Hits New 52-Week High (PRGO) at TheStreet
14-May-13 01:28PM  InPlay: Perrigo notches new session high of 120.15 between its multi-year close high and last week's intraday high at 120.08/120.30 Briefing.com
13-May-13 10:54AM  Perrigo Launches First-Ever Industry Marketing Campaign For Store Brand OTC Medications PR Newswire
11-May-13 06:43PM  These 4 Stocks Saw Trading Price Swings This Past Week Post Earnings at Wall St. Cheat Sheet
01:04PM  PERRIGO CO Financials EDGAR Online Financials
10-May-13 03:28PM  Perrigo Becomes #16 Most Shorted Nasdaq 100 Component, Replacing Intuit at TheStreet
10:22AM  Cramer Says Sell Teva Pharmaceutical, But Buy SunTrust Banks and These 2 Stocks at Wall St. Cheat Sheet
06:00AM  Cramer's Top Stock Picks: PRGO OPEN YELP GRPN at TheStreet
01:31AM  PERRIGO CO Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits EDGAR Online
09-May-13 08:17PM  Cramer's 'Mad Money' Recap: Looking for Real Leaders at TheStreet
06:15PM  [video] Perrigo CEO: Mucinex Product Will Be a Big Winner at CNBC
06:14PM  Cramer's Trend Watch: Store Brand Drugs at CNBC
09:07AM  Perrigo Company Earnings Call Nuggets: Consumer Business and Cash Priorities at Wall St. Cheat Sheet
07-May-13 05:01PM  Perrigo Company (PRGO): Today's Featured Health Care Laggard at TheStreet
03:01PM  Perrigo Management Discusses Q3 2013 Results - Earnings Call Transcript at Seeking Alpha
01:03PM  4 Stocks Pushing The Drugs Industry Downward at TheStreet
12:10PM  Earnings Miss at Perrigo Zacks
11:43AM  [video] Tuesday's Earnings Scorecard at CNBC
09:46AM  Perrigo Co. Earnings: Heres Why Shares are Down Now at Wall St. Cheat Sheet
07:53AM  BRIEF-Perrigo shares down following results at Reuters
07:48AM  InPlay: Perrigo misses by $0.02, misses on revs; reaffirms FY13 EPS guidance Briefing.com
07:43AM  Perrigo Reports Record Revenue and Adjusted Earnings PR Newswire
07:23AM  Perrigo - A Healthy Bet For Your Portfolio at Seeking Alpha
07:07AM  Q3 2013 Perrigo Company Earnings Release - 08:00 am ET CCBN
01:38AM  PERRIGO CO Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
06-May-13 03:00PM  Perrigo Likely to Report In Line Earnings Zacks
10:10AM  Forbes Earnings Preview: Perrigo Company at Forbes
03-May-13 05:43PM  Perrigo Goes With $0.09 Quarterly Dividend at Motley Fool
02-May-13 12:47PM  Daily Dividend Report: HAR, STX, STJ, PRGO, RDS at Forbes
11:31AM  Key for Big Generic Players is Focusing on Higher Value Opportunities that Provide Sustainable Cash Flows: Expert Analyst David Amsellem Discusses the Pharmaceutical Sector with The Wall Street Transcript Wall Street Transcript
08:40AM  Perrigo Company Announces Quarterly Dividend PR Newswire
01-May-13 09:55AM  3 Healthcare Picks From Janus Fund at Motley Fool
30-Apr-13 04:49PM  Scared of a Market Fall? Watch These Defensive Growth Stocks at Motley Fool
27-Apr-13 03:06PM  AbbVie Q1: Story of Humira and the 7 Dwarfs at Motley Fool
26-Apr-13 02:10PM  Covidien's 2Q Earnings Beat Zacks
25-Apr-13 02:00PM  Stryker's 1Q Earnings Beat Est.; Sales Lag Zacks
24-Apr-13 06:20PM  How Will AbbVie's Earnings Fare? at Motley Fool
23-Apr-13 02:19PM  Perrigo Company To Release Third Quarter Fiscal Year 2013 Results On May 7, 2013 PR Newswire
22-Apr-13 09:37AM  Is Perrigo a Stealth Superstar? at Wall St. Cheat Sheet
17-Apr-13 01:45PM  Covidien Collaborates with VIDA Zacks
14-Apr-13 12:45AM  My Thoughts On Taro at Seeking Alpha
12-Apr-13 02:14PM  Landmark Judgment Could Give These Stocks a Boost at Motley Fool
04-Apr-13 10:28AM  Valeant EPS Outlook Hit By Surprise Generic Approval at Investor's Business Daily
03-Apr-13 07:58AM  Perrigo Touches 52-Week High Zacks
02-Apr-13 04:13PM  Perrigo Buys Velcera Zacks
01:20PM  Perrigo Achieves #179 Analyst Rank, Surpassing Microchip Technology at Forbes
12:29PM  Perrigo Stock Hits New 52-Week High (PRGO) at TheStreet
01-Apr-13 05:54PM  Perrigo Closes Acquisition of Pet Health Products Company at Motley Fool
10:49AM  Perrigo Acquisition Of Velcera, Inc. -- Known For Its PetArmor® Franchise Of Flea And Tick Treatments -- Closes Today PR Newswire
09:17AM  Perrigo Company Closes Acquisition Of Companion Animal Health Company, Velcera, Inc. PR Newswire
22-Mar-13 09:00AM  The Pomerantz Firm, Glancy Binkow & Goldberg LLP, and Robbins Geller Rudman & Dowd LLP announce the Notice of Proposed Settlement of the In re: Perrigo Company Securities Litigation PR Newswire
21-Mar-13 02:08PM  Perrigo Ships Mucinex Generic Zacks
18-Mar-13 09:00AM  Perrigo to Begin Shipments of Guaifenesin Extended-Release 600mg Tablets, the First Store Brand Equivalents to Mucinex® 600mg Extended Release Tablets PR Newswire
13-Mar-13 06:34PM  Will Testosterone Fuel Biotech's Next Great Race? at Motley Fool
11-Mar-13 12:32PM  Cadence: Potential Near-Term Catalyst For The Stock at Seeking Alpha
11:46AM  Perrigo Company To Present At The Barclays Global Healthcare Conference PR Newswire
07-Mar-13 05:01PM  Perrigo Company (PRGO): Today's Featured Health Care Laggard at TheStreet
26-Feb-13 09:54AM  Perrigo Stock To Go Ex-dividend Tomorrow (PRGO) at TheStreet
25-Feb-13 05:00PM  Perrigo Company (PRGO): Today's Featured Drugs Winner at TheStreet
02:12PM  Perrigo Company To Present At The RBC Global Healthcare Conference PR Newswire
01:33PM  Atlas Energy Upgraded to Outperform and 3 Upgraded Stocks on the Move at Wall St. Cheat Sheet
01:15PM  [video] Analyze the Analysts! at CNBC
12:06PM  Stocks Mixed Near Midday; Dillard's, 3D Systems Down at Investor's Business Daily
12:05PM  4 Stocks Pushing The Drugs Industry Higher at TheStreet
10:40AM  Reminder - Perrigo Company (PRGO) Goes Ex-Dividend Soon at Forbes
09:54AM  [video] Cramer's Six in 60: International Paper, BlackRock, and More! at CNBC
06:23AM  Perrigo upgraded to Buy from Neutral at UBS theflyonthewall.com
02:57AM  Perrigo upgraded by UBS Briefing.com
23-Feb-13 10:42AM  Is AbbVie Wasting Your Money? at Motley Fool
20-Feb-13 04:38PM  Patent Challenge from Perrigo Zacks
19-Feb-13 03:35PM  Strong Long Term Prospects With This Defensive Growth Play at Motley Fool
09:21AM  InPlay: Perrigo confirms first to file patent challenge for generic version of testosterone gel 1.62% Briefing.com
09:19AM  Perrigo Confirms First to File Patent Challenge for Generic Version of Testosterone Gel 1.62% PR Newswire
13-Feb-13 09:02AM  The Zacks Analyst Blog Highlights: MasterCard, Visa, Heartland Payment Systems, Total System Services and Perrigo Zacks
12-Feb-13 03:43PM  Perrigo in Expansion Mode Zacks
11:04AM  Perrigo Company To Present At The Leerink Swann Global Healthcare Conference PR Newswire
04:19AM  Cumberland Pharmaceuticals: A Rare Value Stock In The Drug Industry at Seeking Alpha
03:00AM  Cyber Attacks a Boon to Radware Sales: Israel Overnight at Bloomberg
11-Feb-13 06:58PM  Cyber Attacks a Boon to Radware Sales: Israel Overnight at Bloomberg
05:00PM  Perrigo Company (PRGO): Today's Featured Drugs Winner at TheStreet
11:57AM  Perrigo will buy UK's Rosemont Pharma for $283M AP
09:45AM  Perrigo buys UK's Rosemont Pharma for $283 million at Reuters
09:44AM  UPDATE 1-Perrigo buys UK's Rosemont Pharma for $283 mln at Reuters
08:57AM  Perrigo buys UK's Rosemont Pharma for $283 million at Reuters
08:57AM  Perrigo buys UK's Rosemont Pharma for $283 mln at Reuters
08:44AM  InPlay: Perrigo acquires U.K.-based Rosemont Pharmaceuticals Ltd. For GBP180 mln or $283 mln in cash; expected to be $0.08 accretive to adjusted EPS for the remainder of fiscal 2013; co raises FY13 guidance to reflect acquisition Briefing.com
08:43AM  Perrigo Company Acquires U.K.-based Rosemont Pharmaceuticals Ltd. For Approximately £180 Million Or $283 Million PR Newswire
10-Feb-13 04:17PM  "Stock Market Joe" at Motley Fool
08-Feb-13 10:53AM  TARO Continues to Post Strong Results at Motley Fool
07-Feb-13 09:02AM  A Hidden Reason Perrigo's Future Looks Bright at Motley Fool
06-Feb-13 05:08PM  FDA Clears Testosterone Gel Zacks
Perrigo Company, through its subsidiaries, develops, manufactures, and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, and active pharmaceutical ingredients (API) worldwide. The company operates in four segments: Consumer Healthcare, Nutritionals, Rx Pharmaceuticals, and API. The Consumer Healthcare segment offers a line of OTC pharmaceutical products in the areas of analgesics, cough/cold/allergy/sinus, gastrointestinal, and smoking cessation, as well as in the areas of feminine hygiene, diabetes care, and dermatological care. The Nutritionals segment develops, manufactures, markets, and distributes infant and toddler formula products, infant and toddler foods, and oral electrolyte solution products, as well as vitamin, mineral, and dietary supplement products. The Rx Pharmaceuticals segment develops, manufactures and markets a portfolio of generic prescription drug products in topical dosage forms, such as creams, ointments, lotions, gels, shampoos, foams, suppositories, sprays, liquids, suspensions, solutions, and powders, as well as controlled substances, injectables, hormones, and oral liquids and oral solid dosage forms. The API segment develops, manufactures, and markets API used by the generic drug industry and branded pharmaceutical companies. Perrigo Company also manufactures and markets branded prescription drugs; and imports pharmaceutical, diagnostics, and other medical products. The company sells its products through chain drug stores, wholesalers, distributors, hospital systems, and group purchasing organizations, as well as retail drug, supermarket, and mass merchandise chains. It has joint development agreements with Medicis Pharmaceutical Corporation, and M. Arkin, Ltd. Perrigo Company was founded in 1887 and is headquartered in Allegan, Michigan.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Shah JatinSr VP & Chief Scientific OfficMay 17Option Exercise15.473,12048,2663,520May 21 03:19 PM
Shah JatinSr VP & Chief Scientific OfficMay 17Sale119.602,268271,2601,900May 21 03:19 PM
KINGMA TODD WExecutive VP, General CounselMay 16Sale120.211,400168,29817,065May 20 08:40 AM
PAPA JOSEPH CPresident and CEOMay 15Option Exercise35.855,000179,250105,000May 17 12:12 PM
PAPA JOSEPH CPresident and CEOMay 15Sale120.515,000602,567100,000May 17 12:12 PM
Kochan SharonExecutive VP U.S. GenericsMay 14Option Exercise58.822,647155,6978,139May 16 03:02 PM
Kochan SharonExecutive VP U.S. GenericsMay 14Sale119.642,647316,6875,492May 16 03:02 PM
Shah JatinSr VP & Chief Scientific OfficMay 14Sale119.773,672439,7851,490May 16 03:06 PM
Gottfried RanDirectorMay 13Option Exercise59.742,224132,86213,833May 15 10:16 AM
Stewart Michael RobertSr. VP Global Human ResourcesMay 13Option Exercise20.501,56031,9801,560May 15 10:17 AM
Stewart Michael RobertSr. VP Global Human ResourcesMay 13Sale119.684,092489,7210May 15 10:17 AM
Gottfried RanDirectorMay 13Sale119.532,224265,84311,609May 15 10:16 AM
Brown Judy LExecutive VP & CFOMay 07Option Exercise30.062,50075,15019,933May 09 10:23 AM
Brown Judy LExecutive VP & CFOMay 07Sale116.862,500292,15017,433May 09 10:23 AM
KINGMA TODD WExecutive VP, General CounselMay 03Option Exercise35.851,25044,81319,715May 07 12:29 PM
KINGMA TODD WExecutive VP, General CounselMay 03Sale119.691,250149,61318,465May 07 12:29 PM
PAPA JOSEPH CPresident and CEOApr 09Option Exercise30.065,000150,300110,645Apr 11 02:49 PM
PAPA JOSEPH CPresident and CEOApr 09Sale118.4610,6451,261,046100,000Apr 11 02:49 PM
Brown Judy LExecutive VP & CFOApr 02Option Exercise30.062,50075,15019,933Apr 04 05:43 PM
Farrington ThomasSenior VP and CIOApr 02Option Exercise58.8292754,5261,967Apr 04 05:48 PM
Brown Judy LExecutive VP & CFOApr 02Sale119.072,500297,67517,433Apr 04 05:43 PM
Farrington ThomasSenior VP and CIOApr 02Sale120.00927111,2401,040Apr 04 05:48 PM
PAPA JOSEPH CPresident and CEOMar 12Option Exercise30.065,000150,300110,645Mar 14 04:15 PM
PAPA JOSEPH CPresident and CEOMar 12Sale116.3315,0001,744,942105,645Mar 14 04:15 PM
Yu LouisSenior VP Global QualityMar 06Option Exercise30.061,79553,95810,966Mar 08 01:57 PM
Yu LouisSenior VP Global QualityMar 06Sale116.071,795208,3489,171Mar 08 01:57 PM
Brown Judy LExecutive VP & CFOMar 05Option Exercise30.062,50075,15019,933Mar 07 02:28 PM
MORRIS HERMAN JRDirectorMar 05Sale114.7520022,9502,400Mar 07 04:13 PM
Zilberfarb Ben-ZionDirectorMar 05Sale115.092,790321,1102,553Mar 07 02:32 PM
Brown Judy LExecutive VP & CFOMar 05Sale115.422,500288,54717,433Mar 07 02:28 PM
PAPA JOSEPH CPresident and CEOFeb 14Option Exercise30.065,000150,300120,645Feb 19 12:36 PM
PAPA JOSEPH CPresident and CEOFeb 14Sale112.075,000560,369115,645Feb 19 12:36 PM
Yu LouisSenior VP Global QualityFeb 12Option Exercise20.503,32868,22412,499Feb 14 11:56 AM
Yu LouisSenior VP Global QualityFeb 12Sale111.573,328371,3159,171Feb 14 11:56 AM
PAPA JOSEPH CPresident and CEOJan 17Option Exercise30.065,000150,300120,645Jan 22 02:37 PM
PAPA JOSEPH CPresident and CEOJan 17Sale104.505,000522,493115,645Jan 22 02:37 PM
Jamison Scott FExecutive Vice President PBMJan 03Option Exercise108.021,000108,0203,361Jan 04 12:41 PM
PAPA JOSEPH CPresident and CEODec 14Option Exercise23.1715,000347,595130,645Dec 18 04:58 PM
PAPA JOSEPH CPresident and CEODec 14Sale103.9415,0001,559,118115,645Dec 18 04:58 PM
JANDERNOA MICHAEL JDirectorDec 07Sale102.49105,50010,812,590495,230Dec 11 01:15 PM
JANDERNOA MICHAEL JDirectorDec 06Sale103.5067,5006,986,000609,645Dec 07 03:42 PM
JANDERNOA MICHAEL JDirectorDec 05Sale105.0072,0007,559,705973,145Dec 07 03:42 PM
Gottfried RanDirectorDec 04Option Exercise39.623,053120,96014,662Dec 06 10:13 AM
Gottfried RanDirectorDec 04Sale104.473,053318,94711,609Dec 06 10:13 AM
BRLAS LAURIEDirectorDec 03Sale102.7710,7571,105,4657,424Dec 05 01:36 PM
Farrington ThomasSenior VP and CIONov 29Option Exercise20.5097820,0491,653Dec 03 01:15 PM
Farrington ThomasSenior VP and CIONov 29Sale103.1661363,2381,040Dec 03 01:15 PM
GIBBONS DAVID TDirectorNov 26Option Exercise25.8830,778796,41029,125Nov 28 03:33 PM
KINGMA TODD WExecutive VP, General CounselNov 26Option Exercise30.062,74082,36421,205Nov 28 03:33 PM
KINGMA TODD WExecutive VP, General CounselNov 26Sale103.282,740282,99418,465Nov 28 03:33 PM
GIBBONS DAVID TDirectorNov 26Sale102.2950,7785,194,20411,625Nov 28 03:33 PM
PAPA JOSEPH CPresident and CEONov 15Option Exercise30.0615,000450,900130,645Nov 19 02:04 PM
PAPA JOSEPH CPresident and CEONov 15Sale100.7815,0001,511,747115,645Nov 19 02:04 PM
Kochan SharonExecutive VP U.S. GenericsNov 14Option Exercise20.502,91259,6967,772Nov 16 03:08 PM
MORRIS HERMAN JRDirectorNov 09Sale103.902,000207,80417,980Nov 13 09:23 AM
KINGMA TODD WExecutive VP, General CounselOct 25Option Exercise30.063,500105,21021,965Oct 29 05:17 PM
KINGMA TODD WExecutive VP, General CounselOct 25Sale117.874,500530,43418,465Oct 29 05:17 PM
PAPA JOSEPH CPresident and CEOOct 10Option Exercise30.0615,000450,900130,645Oct 12 11:58 AM
PAPA JOSEPH CPresident and CEOOct 10Sale117.3715,0001,760,554115,645Oct 12 11:58 AM
Brown Judy LExecutive VP & CFOOct 08Option Exercise20.502,67954,92020,812Oct 10 03:30 PM
Brown Judy LExecutive VP & CFOOct 08Sale119.242,679319,44718,133Oct 10 03:30 PM
Farrington ThomasSenior VP and CIOOct 04Option Exercise58.8292654,4671,601Oct 09 08:21 AM
Farrington ThomasSenior VP and CIOOct 04Sale120.00926111,120675Oct 09 08:21 AM
KINGMA TODD WExecutive VP, General CounselSep 25Option Exercise20.503,56573,08323,030Sep 27 08:33 AM
KINGMA TODD WExecutive VP, General CounselSep 25Sale117.283,565418,10319,465Sep 27 08:33 AM
PAPA JOSEPH CPresident and CEOSep 21Option Exercise30.0615,000450,900130,645Sep 25 04:45 PM
PAPA JOSEPH CPresident and CEOSep 21Sale116.5915,0001,748,831115,645Sep 25 04:45 PM
Jamison Scott FExecutive Vice President PBMSep 14Option Exercise112.451,000112,4502,684Sep 18 02:43 PM
Brown Judy LExecutive VP & CFOSep 06Option Exercise20.502,67854,89920,811Sep 07 03:10 PM
Brown Judy LExecutive VP & CFOSep 06Sale110.812,678296,74918,133Sep 07 03:10 PM
KINGMA TODD WExecutive VP, General CounselAug 30Option Exercise20.502,00041,00021,465Sep 04 03:51 PM
HENDRICKSON JOHN TEVP Global Operations & SupplyAug 30Option Exercise20.503,58973,5753,589Sep 04 03:52 PM
PAPA JOSEPH CPresident and CEOAug 30Option Exercise20.5010,000205,000125,645Sep 04 03:52 PM
Needham JeffreySr. VP Commercial Business DevAug 30Option Exercise20.502,08042,6407,268Aug 31 01:46 PM
Needham JeffreySr. VP Commercial Business DevAug 30Sale108.872,080226,4505,188Aug 31 01:46 PM
PAPA JOSEPH CPresident and CEOAug 30Sale109.1710,0001,091,741115,645Sep 04 03:52 PM
HENDRICKSON JOHN TEVP Global Operations & SupplyAug 30Sale108.873,589390,7340Sep 04 03:52 PM
KINGMA TODD WExecutive VP, General CounselAug 30Sale108.872,000217,74019,465Sep 04 03:51 PM
Needham JeffreySr. VP Commercial Business DevAug 29Option Exercise55.016,665366,6158,240Aug 31 01:46 PM
Needham JeffreySr. VP Commercial Business DevAug 29Sale110.349,2241,017,7325,188Aug 31 01:46 PM
Stewart Michael RobertSr. VP Global Human ResourcesAug 28Option Exercise54.333,883210,9594,327Aug 29 02:42 PM
HENDRICKSON JOHN TEVP Global Operations & SupplyAug 28Sale110.666,666737,6330Aug 29 03:17 PM
KINGMA TODD WExecutive VP, General CounselAug 28Sale110.665,000553,27919,465Aug 29 03:12 PM
Kochan SharonExecutive VP U.S. GenericsAug 28Sale110.803,352371,4024,860Aug 29 03:14 PM
Brown Judy LExecutive VP & CFOAug 28Sale110.6512,1801,347,74118,133Aug 29 03:12 PM
Stewart Michael RobertSr. VP Global Human ResourcesAug 28Sale110.907,633846,5332,532Aug 29 02:42 PM
Kochan SharonExecutive VP U.S. GenericsAug 27Option Exercise90.2910,657962,24811,593Aug 29 03:14 PM
Brown Judy LExecutive VP & CFOAug 27Option Exercise110.6620,5752,276,83033,469Aug 29 03:12 PM
Stewart Michael RobertSr. VP Global Human ResourcesAug 27Option Exercise110.665,309587,4946,868Aug 29 02:42 PM
HENDRICKSON JOHN TEVP Global Operations & SupplyAug 27Option Exercise90.2914,2101,283,04410,257Aug 29 03:17 PM
PAPA JOSEPH CPresident and CEOAug 27Option Exercise110.6643,9024,858,195143,902Aug 29 03:14 PM
KINGMA TODD WExecutive VP, General CounselAug 27Option Exercise110.6611,5141,274,13925,057Aug 29 03:12 PM
Needham JeffreySr. VP Commercial Business DevAug 27Option Exercise110.669,025998,7079,083Aug 29 03:13 PM
Yu LouisSenior VP Global QualityAug 27Option Exercise110.663,313366,6178,803Aug 29 03:13 PM
Shah JatinSr VP & Chief Scientific OfficAug 27Option Exercise110.666,191685,0968,273Aug 29 03:16 PM
HENDRICKSON JOHN TEVP Global Operations & SupplyAug 27Sale109.203,591392,1376,666Aug 29 03:17 PM
Kochan SharonExecutive VP U.S. GenericsAug 27Sale110.273,381372,8208,212Aug 29 03:14 PM
PAPA JOSEPH CPresident and CEOJul 18Option Exercise22.9010,000228,992108,437Jul 20 02:42 PM
PAPA JOSEPH CPresident and CEOJul 18Sale114.9510,0001,149,452100,000Jul 20 02:42 PM
PAPA JOSEPH CPresident and CEOJun 20Option Exercise20.5010,000205,000110,000Jun 22 09:30 AM
open in yahoo | open in reuters | open in google